

Surzebiclimab

Cat. No.:	HY-P99962
Target:	Mucin
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity ($K_D=0.36$ nM) and specificity. Surzebiclimab can be used in research of cancer ^[1] .
In Vitro	Surzebiclimab (BGB-A425; 0.1-100 $\mu\text{g}/\text{mL}$) efficiently blocks the interactions between Tim-3 and PtdSer. Surzebiclimab enhances IFN- γ production of primary T cells and NK-mediated cytotoxicity against tumor cells ^[1] . Surzebiclimab augments T-cell response to allogeneic antigens either alone or in combination with an anti-PD-1 antibody BGB-A317. Surzebiclimab can also induce the internalization of Tim-3 receptor on cell surface ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Surzebiclimab (BGB-A425) in combination with BGB-A317 inhibits tumor growth in a mouse xenograft cancer model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tong Z, et, al. Abstract 2628: BGB-A425: a humanized anti-human Tim-3 antibody that exhibits strong immune cell activation. Cancer Res. 2017;77:(13_Supplement):2628.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA